Movement Disorders Centre Brno and First Department of Neurology, Faculty of Medicine Masaryk University Brno, St. Anne's Hospital Pekarska 53, 656 91 Brno, Czech Republic.
J Neural Transm (Vienna). 2012 Mar;119(3):373-80. doi: 10.1007/s00702-011-0683-9. Epub 2011 Jul 17.
EWO (Epidemiology of Wearing-Off symptoms among the population of Parkinson's disease (PD) patients on L-DOPA) is a multicentric, non-interventional, epidemiological and exploratory trial, focused on patients with PD who are treated with L-DOPA. The primary objective is the estimation of wearing-off symptoms (based on WOQ-9 questionnaire and assessment by neurologists) among PD patients who are treated with L-DOPA. From September 30, 2007 to June 30, 2008 altogether 563 valid records of PD patients were collected in movement disorders centers (Level A and Level B centers). Wearing-off symptoms were observed in 66.7% of PD patients (neurologists' assessment) and in 90.6% of PD patients (WOQ-9 questionnaire). The biggest discrepancy was found in PD patients treated with L-DOPA for 0-2 years. The probability of detecting wearing-off by the neurologists strongly correlated with the highest number of positive responses in the WOQ-9 marked by PD patients. There was significant difference in the diagnosis of wearing-off between Level A centers (77.7%) and Level B centers (62.0%). When motor and non-motor symptoms in the WOQ-9 were considered, the difference between neurologists came from the detection of non-motor symptoms (lower in the Level B centers). The neurologists' assessment of wearing-off symptoms and PD patients' subjective evaluation of the WOQ-9 is based on the experience of the neurologist and on the detection of the non-motor symptoms of wearing-off. Careful explanation of the WOQ-9 questionnaire and improved awareness of the non-motor symptoms of wearing-off is strongly suggested.
EWO（帕金森病患者左旋多巴治疗中的症状波动的流行病学研究）是一项多中心、非干预性、观察性和探索性研究，主要关注接受左旋多巴治疗的帕金森病患者。主要目的是评估接受左旋多巴治疗的帕金森病患者的症状波动（基于 WOQ-9 问卷和神经病学家的评估）。从 2007 年 9 月 30 日至 2008 年 6 月 30 日，共在运动障碍中心（A 级和 B 级中心）收集了 563 例有效记录的帕金森病患者。在接受左旋多巴治疗的帕金森病患者中，有 66.7%（神经病学家评估）和 90.6%（WOQ-9 问卷）观察到症状波动。在接受左旋多巴治疗 0-2 年的帕金森病患者中差异最大。神经病学家检测到症状波动的概率与 PD 患者在 WOQ-9 中标记的最高阳性反应数强烈相关。A 级中心（77.7%）和 B 级中心（62.0%）在症状波动的诊断上存在显著差异。当考虑 WOQ-9 中的运动和非运动症状时，神经病学家之间的差异来自非运动症状的检测（B 级中心较低）。神经病学家对症状波动的评估和 PD 患者对 WOQ-9 的主观评估基于神经病学家的经验和对非运动症状波动的检测。强烈建议对 WOQ-9 问卷进行仔细解释，并提高对非运动症状波动的认识。
